$54.65
0.00%
Nasdaq, Fri, Dec 19 2025
ISIN
US00973Y1082
Symbol
AKRO

Akero Therapeutics Inc Stock price

$54.65
+0.31 0.57% 1M
-0.25 0.46% 6M
+26.83 96.44% YTD
+26.25 92.43% 1Y
+15.88 40.94% 3Y
+29.03 113.31% 5Y
+38.65 241.56% 10Y
+38.65 241.56% 20Y
Nasdaq, Closing price Fri, Dec 19 2025
+0.00 0.00%
ISIN
US00973Y1082
Symbol
AKRO
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$737.8m
Shares outstanding
80.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
90.8%
Return on Equity
-33.6%
ROCE
-34.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-354.2m
EBIT
$-330.0m | $-345.6m
Net Income
$-292.8m | $-303.6m
Free Cash Flow
$-250.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -24.1%
EBIT
-22.4% | -21.1%
Net Income
-23.6% | -20.5%
Free Cash Flow
-17.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.6
FCF per Share
$-3.1
Short interest
5.4%
Employees
63
Rev per Employee
$0.0
Show more

Is Akero Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Akero Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Akero Therapeutics Inc forecast:

8x Buy
50%
8x Hold
50%

Analyst Opinions

16 Analysts have issued a Akero Therapeutics Inc forecast:

Buy
50%
Hold
50%

Financial data from Akero Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 43 43
15% 15%
-
- Research and Development Expense 287 287
24% 24%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -330 -330
22% 22%
-
Net Profit -293 -293
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akero Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akero Therapeutics Inc Stock News

Neutral
GlobeNewsWire
16 days ago
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD p...
Neutral
Business Wire
about one month ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Conti...
Neutral
PRNewsWire
about one month ago
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ --  Berger Montague PC  advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Mont...
More Akero Therapeutics Inc News

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Andrew Cheng
Employees 63
Founded 2017
Website akerotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today